Mitsou Evgenia, Klein Jacob
Department of Molecular Chemistry and Materials Science, Weizmann Institute of Science, Hertzl Street 234, Rehovot, 7610001, Israel.
Institute of Chemical Biology, National Hellenic Research Foundation, 48, Vassileos Constantinou Ave., Athens, 11635, Greece.
Small. 2025 Apr;21(17):e2410060. doi: 10.1002/smll.202410060. Epub 2025 Mar 27.
Osteoarthritis (OA) is the most common degenerative disease of the joints, causing significant disability and socio-economic burden in the aging population. Simultaneously, however, it is a common occurrence in younger individuals, initiated by joint injuries or obesity alongside other factors. Intravenous and oral pharmaceutical OA management have both been associated with systemic adverse effects, thereby resulting in a growing interest in intra-articular (IA) treatment. IA-administered drugs circumvent the requirement for high dosage, offering immediate access to the site of interest while minimizing any unfavorable effects. Nonetheless, IA-injected drugs, administered in their free form, present low retention time in the knee joint raising the need for multiple injection dosage regimens, while their capability to target the cartilage or specific cell populations is limited. Liposomes, due to their unique characteristics and tunable nature, have proven to be excellent candidates for the management of knee OA. This review explores the last decade's research on the efficacy of various IA liposomal formulations, investigating their multifaceted properties as pharmaceutical carriers, lubricating agents, and a basis for combinatorial approaches paving the way to novel treatment solutions for OA.
骨关节炎(OA)是最常见的关节退行性疾病,在老年人群中导致严重的残疾和社会经济负担。然而,与此同时,它在年轻人中也很常见,由关节损伤、肥胖以及其他因素引发。静脉内和口服药物治疗OA均与全身不良反应相关,因此人们对关节内(IA)治疗的兴趣日益增加。关节内给药的药物无需高剂量,可直接作用于目标部位,同时将不良反应降至最低。尽管如此,以游离形式给药的关节内注射药物在膝关节中的保留时间较短,需要多次注射给药方案,而且它们靶向软骨或特定细胞群体的能力有限。由于脂质体具有独特的特性和可调节性,已被证明是治疗膝关节OA的理想选择。本综述探讨了过去十年中各种关节内脂质体制剂疗效的研究,研究了它们作为药物载体、润滑剂以及组合方法基础的多方面特性,为OA的新型治疗方案铺平道路。